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to differentiate into pancreatic beta cells. For this particular
lineage, more effort is still required to stress the importance
of developing an efﬁcient, reproducible, easy, and cost-effective
differentiation protocol to obtain more mature, homogeneous,
and functional insulin-secreting cells. In addition, microRNAs
(miRNAs) have emerged as a class of small non-coding RNAs
that regulate many cellular processes, including pancreatic dif-
ferentiation. Some miRNAs are known to be preferentially ex-
pressed in islets. Of note, miR-375 and miR-7 are two of the
most abundant pancreatic miRNAs, and they are necessary
for proper pancreatic islet development. Here we provide new
insight into speciﬁc miRNAs involved in pancreatic differenti-
ation. We found that miR-7 is differentially expressed during
the differentiation of human embryonic stem cells (hESCs)
into a beta cell-like phenotype and that its modulation plays
an important role in generating mature pancreatic beta cells.
This strategy may be exploited to optimize the potential for
in vitro differentiation of hESCs into insulin-producing beta-
like cells for use in preclinical studies and future clinical appli-
cations as well as the prospective uses of miRNAs to improve
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https://doi.org/10.1016/j.omtn.2018.06.002.
5These authors contributed equally to this work.
Correspondence: Abdelkrim Hmadcha, Andalusian Center for Molecular Biology
and Regenerative Medicine (CABIMER), Avda. Américo Vespucio 24, Parque
Cientíﬁco y Tecnológico Cartuja, Sevilla 41092, Spain.
E-mail: karim.hmadcha@cabimer.esINTRODUCTION
MicroRNAs (miRNAs) were identiﬁed in Caenorhabditis elegans as
essential regulators of development,1 and the ﬁrst miRNAs described
in animals were lin-4 and let-7.2–6 To control the expression of pro-
tein-coding genes, miRNA genes are primarily transcribed by RNA
polymerase II into long precursor molecules that are processed
via RNase III enzymes Drosha and Dicer into mature miRNAs
(22 nt).7,8
These small non-coding RNAs are critical for translational regulation
within the cell, and they play a key role in regulating several cellular
processes, including differentiation, proliferation, and signal trans-
duction.9–11 This type of regulation occurs through base pairing of
miRNAs to target sites in the 30 UTR of mammalian protein-coding
genes; thus, miRNAs exert control as central regulators of develop-Molecular Therapy
This is an open access article under the CC BY-NC-ment.12–14 In embryonic stem cells (ESCs), miRNAs play a role in
maintaining pluripotency and proliferation, as well as differentiation
and cell fate determination.15–18
During pancreatic islet development, many gene expression changes
related to efﬁcient differentiation and function of the pancreas
occur.19,20 Although the molecular mechanisms underlying pancre-
atic development remain unclear, recent discoveries related to
miRNA-dependent post-transcriptional gene regulation have opened
a new area of research, such that miRNAs are very likely to have reg-
ulatory roles in the differentiation, maturation, and physiology of
pancreatic islet cells.21,22
Proper pancreatic islet development is controlled not only by key
transcription factors and speciﬁc signaling pathways but also by
miRNAs, as evidenced by the generation of pancreas-speciﬁc
Dicer1-knockout mice.23 A few miRNAs are preferentially expressed
in speciﬁc tissue, and, as such, some miRNAs were found to be pref-
erentially expressed in islets, with miR-375 and miR-7 being the most
abundant endocrine miRNAs in rat and human islets.21–25 Several
miRNAs are highly expressed during human pancreatic islet develop-
ment, and they are known to play a functional role in pancreatic beta
cell development and function: miR-15a induces insulin biosynthesis
by inhibiting UCP-2 gene expression;26 miR-30d has been described
as a glucose-dependent regulator of insulin transcription;27 miR-124a
is a key regulator of beta cell physiology through Foxa2 and preproin-
sulin gene expression;28 miR-9 is a key factor in modulating Sirt1
expression and, thus, in regulating exocytosis and insulin secretion;29
miR-373 overexpression promotes human ESC (hESC) differ-
entiation toward the mesendodermal lineage;30 miR-24, miR-26,: Nucleic Acids Vol. 12 September 2018 ª 2018 The Author(s). 463
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Nucleic AcidsmiR-182, and miR-148 are regulators of insulin transcription in
cultured islet or beta cells;31 miR-375 is required for normal glucose
homeostasis and, thus, is implicated not only in pancreatic islet devel-
opment but also in mature islet function;21,22,32,33 and miR-7 is the
most abundant endocrine miRNA and is expressed at high levels dur-
ing human pancreatic islet development,21,22,25 and inhibition of
miR-7 results in decreased beta cell numbers and glucose intolerance
in the developing pancreas.34 Previous studies have shown that the
overexpression of miR-375 promotes pancreatic endocrine differenti-
ation of ESCs and provides evidence that constitutive miR-375 over-
expression in hESCs leads to the expression of beta cell markers, as
well as insulin release in response to glucose in islet-like clusters.35
Furthermore, the expression of miR-7 in human fetal pancreas in-
creases at weeks 14–18, coinciding with the induction of PDX-1
and other key genes required for endocrine cell fate speciﬁcation,21
and these data suggest that a novel mechanism controls endocrine
cell differentiation.
Pancreatic beta cell speciﬁcation depends on a succession of signaling
and transcription factor-activating events that are coordinated in a
spatial and temporal manner during pancreatic development. In
this study, we induce in vitro pancreatic differentiation of hESCs
through a multistep protocol by adding growth factors and/or chem-
ical compounds that activate speciﬁc signaling pathways and induce
the expression of transcription factors at the suitable stage of differen-
tiation. However, because several reports implicated miRNAs in
pancreatic differentiation, we examined the expression proﬁles of
miRNAs in hESCs and the resulting differentiated cells, as well as
the involvement of miR-7 in the different steps of the differentiation
process.
RESULTS
miRNA Signature in hESC Samples during Differentiation
To understand the molecular basis of pancreatic induction, we per-
formed microarray assay to further depict the molecular changes in
HS181 hESCs during multi-staged pancreatic commitment. This
array analysis aimed to evaluate miRNA expression during hESC dif-
ferentiation into insulin-producing beta-like cells36 and in human
adult islets and pancreas. A total of 2,689 probes was used and 850
miRNAs were detected.
To characterize the expression of miRNAs possibly implicated in
pancreatic development and to determine whether gene expression
proﬁles differ among cells, we compared miRNA expression among
undifferentiated (UN)-, differentiated (DD)-, and spontaneous differ-
entiated (SD)-hESCs after culturing for 22 days (Figure 1A). At ﬁrst,
hierarchical clustering was used to display the differentially expressed
miRNAs (rows) and differentiated states of hESCs (columns) using
half-square Euclidean distance as a similarity measure. Based on
the hierarchical clustering of our expression data, our results revealed
distinct clusters with a diverse expression proﬁle.We could also detect
genes that were most dynamically changed in their expression pat-
terns during sequential differentiation into insulin-producing beta-
like cells. When hESCs committed to insulin-producing beta-like cells464 Molecular Therapy: Nucleic Acids Vol. 12 September 2018(DD-hESCs), miRNAs related to pancreatic development, such as
miR-375 and miR-7, one of the most abundant miRNAs in the
pancreas, were highly upregulated, whereas miRNAs related to plu-
ripotency, such as the miR-302 family, one of the key maternal mate-
rials essential for maintenance and renewal of hESC pluripotency,
were downregulated (Figure 1A).
To determine whether there is any link between human adult pancre-
atic lineage and our hESC pancreatic lineage differentiation, we
compared our microarray data with miRNAs preferentially expressed
in human pancreas using isolated human islets of Langerhans and
DD-hESCs to identify distinct and/or similar miRNAs (Figure 1B).
Probes were separated into seven clusters by hierarchical clustering
analysis. Assuming that miRNA abundance is an indicator of their
biological function, our results suggest that the preferential expres-
sion of certain miRNAs in hESCs indicates a potential role in self-
renewal and maintenance of pluripotency (clusters 5 and 6), whereas
the preferential expression of other miRNAs in islets possibly indi-
cates involvement in pancreatic islet development and function (clus-
ter 1). The clustering result showed that pancreas and islets shared a
slight similarity in their expression proﬁles with hESC-derived insu-
lin-producing cells (clusters 2, 3, 4, and 7), suggesting acquired prop-
erties similar to pancreatic polypeptide (PP) cells.
To determine whether miRNAs might contribute to the switch in
gene expression programs, we compared the level of these small
non-coding RNAs in DD-hESCs and SD-hESCs: the level scores
were converted into fold changes with log2 base. We detected 850
miRNAs and found that 61 of these miRNAs displayed expression
changes larger than 0.58-fold (p < 0.05) during the differentiation
of hESCs into insulin-producing beta-like cells. Of these, 19 were up-
regulated and 42 were downregulated in the DD-hESC group (Fig-
ure 1C; Table S1).
We found that several downregulated miRNAs belonged to the ESC-
speciﬁc cell cycle-regulating (ESCC) family of miRNAs (i.e., miR-302
family), which is essential for hESC maintenance and renewal. In
contrast, upregulation of a characteristic set of miRNAs constitutes
a small group of miRNAs and is, therefore, ideally suited to coordi-
nate modiﬁcations in gene expression programs that occur during
hESC differentiation into insulin-producing beta-like cells. Based
on these observations, we selected miRNAs belonging to this group
as well as a group of individual miRNAs showing dramatic changes
between the pancreas and islets for further analysis.
Identification of miRNAs Enriched in the Pancreas
We used microarray expression results from a subset of miRNAs to
identify those that were exclusively expressed and most abundant
in pancreatic tissue and islets (Figure 2A). We identiﬁed several
miRNAs preferentially expressed in human pancreatic islets, and
we generated miRNA expression proﬁles of the pancreas. miRNA
proﬁling from pancreatic samples identiﬁed the most abundant
miRNAs, indicating that these miRNAs play a signiﬁcant role in
pancreatic development and function.
Figure 1. Microarray Analysis of hESC Differentiation into Insulin-Producing Beta-like Cells
(A) Heatmap summarizing patterns of expression for miRNAs loci that were differentially expressed in all samples of HS181 and adult human pancreas (n = 2–3 per group).
Scaled expression value, denoted as the row Z score, is plotted in a red-green color scale with green indicating increased expression and red indicating decreased
expression. (B) Heatmap comparing differentially expressedmiRNAs among DD-hESCs, adult human pancreas, and pancreatic islets (n = 2–3 per group). Scaled expression
value, denoted as the row Z score, is plotted in a red-blue color scale with red indicating increased expression and blue indicating decreased expression. Hierarchical
clustering of miRNAs (rows) and samples (columns) is based on their expression profiles using the open-source data analysis Multiple Experiment Viewer (MeV) software
package (average linkage and Euclidean distance as similarity measure). Expression data are shown for miRNAs with log2(fold change) differences of expression >0.58
(p < 0.05). (C) Scatterplot shows differentially expressed miRNAs log2(fold change) between DD- and SD-hESCs (p < 0.05). Selected miRNAs up- and downregulated in
HS181 are highlighted (n = 2–3 per group).
www.moleculartherapy.orgA total of 29 miRNAs were found to be expressed in the primary
screening (e.g., miR-148a, miR-7, miR-375, miR-16, miR-26a, miR-
30d, miR-15b, miR-376a, and miR-195) and 21 miRNAs were found
to be downregulated (e.g., miR-29a/b/c, miR-15a, and miR-200a/c).
We investigated all miRNAs that were upregulated and downregu-
lated in pancreatic islets by qRT-PCR analysis in order to conﬁrm
the differentially and commonly expressed miRNAs in the pancreas
(Figure 2B). We conﬁrmed high expression levels of miRNAs thatwere previously known to be abundant in pancreatic tissue, such as
miR-15a, miR-16, and the miR-29 family, and we identiﬁed miRNAs
differentially expressed in islets; 3 miRNAs were highly expressed in
islets with a fold change in expression of islets versus pancreas ranging
from 1.6- to 3.8-fold (relative expression is indicated by the log2
value). Five miRNAs were considered equally expressed with a fold
change ranging from 0.03- to 0.3-fold, and 7 miRNAs were less ex-
pressed in islets with a fold change ranging from 0.6- to 4.8-fold.Molecular Therapy: Nucleic Acids Vol. 12 September 2018 465
Figure 2. Differentially Expressed miRNAs in the Human Islets and Pancreas
(A) Heatmap summarizing differential expression of microarray data for the most highly expressed set of 50 miRNAs in adult human pancreas and pancreatic islets. Scaled
expression value, denoted as the row Z score, is plotted in a rainbow color scale with red indicating increased expression and blue indicating decreased expression. Hi-
erarchical clustering of miRNAs (rows) and samples (columns) is based on their expression profiles using the open-source data analysis Multiple Experiment Viewer (MeV)
software package (average linkage and Euclidean distance as similarity measure). (B) qRT-PCR validation of differentially expressed miRNAs identified using Human miRNA
Microarray Agilent 60-mer SurePrint technology in human adult pancreas and pancreatic islets. miRNA levels were normalized to 60S acidic ribosomal protein P0 (RPLP;
endogenous control) and expressed in fold change (n = 3 per group). Values are shown (mean ± SD). Significant difference between human adult pancreas and pancreatic
islets RNA levels was assessed by one-way ANOVA with Holm-Sı´da´k test, *p < 0.05, **p < 0.01, ***p < 0.0001, and ****p < 0.00001. (C) miRSystem pathway analysis for
upregulatedmiRNAs in pancreatic islets. Pathways targeted by our candidatemiRNAs (miR-7, miR-148, andmiR-375) were predicted using the web-based tool miRSystem,
(legend continued on next page)
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www.moleculartherapy.orgBetween miR-375 and miR-7, which are miRNAs preferentially ex-
pressed in beta cells and known as islet miRNAs, miR-7 was the
most abundant (3.8-fold) in human pancreatic islets (Figure 2B).
Based on the data obtained from the qRT-PCR-based miRNA-
proﬁling analysis, we determined 3miRNAswere upregulated in islets,
miR-7, miR-148a, and miR-375, and, using the miRSystem database,
bioinformatics analysis with target genes of these miRNAs revealed
a set of networks closely related to pancreatic development, as well
as multiple signaling pathways participating in the regulation of insu-
lin synthesis and secretion (Figure 2C; Figure S1). The Database for
Annotation, Visualization and Integrated Discovery (DAVID) tools
were used to identify potentially enriched biological processes (BPs)
among the putative gene targets of the differentially expressed
miRNAs using gene ontology (GO) terms, and to identify the related
pathways using the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway database. Accordingly, GO enrichment analysis re-
vealed functional clusters signiﬁcantly enriched for genes involved in
pancreas development, transport, and secretory processes (Figure 2D).
Besides, KEGG pathway analysis based on these 3 upregulated
miRNAs identiﬁed 10 signaling pathways predicted to be mainly
related to the insulin-signaling pathway (Figure 2E), whichwas largely
consistent with the data from the GO analysis indicated above.
Characterization of Pancreas-Specific miRNA Expression
during In Vitro Differentiation
Based on our microarray analysis of SD-hESCs, in comparison to
DD-hESCs, we identiﬁed various upregulated miRNAs that may
function as regulators of pancreatic differentiation. To deﬁne the
expression pattern of miRNAs in our protocol for pancreatic differen-
tiation, the expression proﬁles of pancreas-speciﬁc miRNAs from
hESCs during differentiation were quantitated using qRT-PCR, and
the expression level of each miRNA was indicated as fold change
over UN-hESCs.
To conﬁrm the sequential differentiation of cultured hESCs, identify
potential novel miRNAs for pancreatic differentiation, and determine
the expression of these miRNAs in hESCs, the expression of pancreas-
speciﬁc miRNAs was analyzed by qRT-PCR at days 0, 5, 14, and 22,
and these cells were then induced to differentiate into hESC-derived
insulin-producing cells for 22 days. Differentially expressed miRNAs
with a p value of 0.05 or lower and at least a 3-fold differential expres-
sion value were deﬁned as differentially expressed between the two
groups (Figure 3A). Consistent with our microarray data, qRT-PCR
analysis indicated that, after hESCs became committed to deﬁnitive
endoderm (DE) in vitro, 3 miRNAs (miR-7, miR-375, and miR-which integrates several databases (KEGG, BIOCARTA, Pathway Interaction Databa
pathways. (D) Data of 3 differentially upregulated miRNAs were processed using miRSys
ontology scatterplots were generated using the open-source online tool REViGO. Bubb
where blue and green bubbles are gene ontology terms with more significant p values
ontology term in the underlying gene ontology database. (E) The predicted KEGG signal
375. The ranking score was obtained by summation of the weight of itsmiRNA times its e
and the y axis represents the top 10 enriched KEGG pathways.373) were progressively upregulated. Moreover, we found that these
miRNAs were dramatically increased in the early stages of the proto-
col and coincided with factors that should induce DE and that these
miRNAs then decreased during endocrine proliferation at day 14.
These hESCs were directed to sequentially differentiate into PP cells
through deﬁnitive and posterior foregut endoderm stages, and the
expression of 3 miRNAs (miR-15a/b and miR-16a) appeared to be
increased during endocrine induction. In the late stages, compared
to that in SD-hESCs, the expression of 2 miRNAs (miR-29b and
miR-148a) reached a peak in DD-hESCs following endocrine prolif-
eration at day 22. Furthermore, our expression proﬁling analyses in
hESC-derived lineage displayed similar expression proﬁles for human
induced pluripotent stem cell (hiPSC)-derived insulin-producing
cells (Figure S2). Taken together, these data suggest that these
miRNAs are likely to be associated with the beta cell-like phenotype
and to be functionally involved in pancreatic differentiation. Accord-
ing to the results obtained by qRT-PCR, miRNA ﬂuorescence in situ
hybridization (FISH) showed that miR-7 and miR-375 were
expressed across a population of cells during the ﬁrst steps of DE
establishment (5 and 11 days) and that their expression decreased
gradually in the next steps (11 and 22 days); however, miR-148a
showed a different expression pattern with increasing expression
levels preferentially in the last steps (11 and 22 days) (Figure 3B).
Modulation of Specific miRNAs in hESCs
miR-7 is a candidate miRNA selected for this study because it is
highly expressed in the developing human pancreas and because its
expression coincides with an exponential increase in pancreatic endo-
crine hormones. Assuming that the abundance of miRNAs is an indi-
cator of their biological function, these ﬁndings indicated a potential
role for miR-7 in endocrine cell differentiation and/or function. How-
ever, our DD protocol reported herein shows very high expression
and then progressively decreased expression of miR-7 during differ-
entiation of the pancreatic endocrine precursors, which supports
the establishment and DE differentiation of hESCs. Here we investi-
gated the effects of miR-7 modulation during differentiation of endo-
crine progenitors and insulin-expressing cells in DD-hESCs and their
further maturation into glucose-responsive beta-like cells.
Therefore, we examined whether miR-7 is able to enhance pancreatic
differentiation in hESCs. Using miRNA mimics (Dharmacon,
miRIDIAN microRNA Mimics), HS181 cells were transiently trans-
fected with a control mimic or miR-7 mimic and incubated for
24 hr in pancreatic differentiation medium (Figure 4A). To ensure
effectiveness of the miR-7 mimic throughout the differentiation pro-
cess, we veriﬁed its persistence after transfection by qRT-PCR fromse, Reactome, and GO molecular function) to predict gene targets and targeted
tem (version 20160513) and DAVID online bioinformatics resource version 6.8. Gene
le color indicates the p value of gene ontology terms (expressed as log10 p value),
than the orange and red bubbles. Bubble size indicates the frequency of the gene
pathways to be regulated by the differentially expressed miR-7, miR-148a, and miR-
nrichmentlog (p value) from the predicted target genes. The x axis represents score
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Figure 3. Differences in miRNA Expression during Differentiation of hESCs
(A) Verification of expression of representative miRNAs by qRT-PCR analysis. RNA was extracted from hESC-derived insulin-producing cells at 0, 5, 14, and 22 days after
various treatments (n = 3–6 per group). miRNA levels were normalized to U48 and expressed in fold change (n = 4–6 per group). Values are shown (mean ± SD). Significant
difference in HS181 miRNA levels between groups was assessed by one-way ANOVA with Holm-Sı´da´k test, *p < 0.05, **p < 0.01, and ***p < 0.001. (B) FISH was used to
visualize the expression of a subset of critical miRNAs at defined stages of differentiation at days 5, 11, and 22: miR-7, miR-375, and miR-148 (red). Nuclei were coun-
terstained with Hoechst (blue).
Molecular Therapy: Nucleic Acidsisolated RNA of transfected and control hESCs. The results conﬁrmed
the signiﬁcant expression levels of miR-7 in transfected hESCs
compared to those in control hESCs. The fold change in the expres-
sion of miR-7 in hESCs transfected for 24 hr was 702-fold, which was
dramatically higher than that of the control group (Figure 4B).
miRNA expression levels were stable after at least 4 days, and, thus,
we hypothesized that the transfected miRNAmimic was valid to eval-
uate its effect in hESC differentiation.
We next wanted to determine how the miR-7 level increases might
affect pancreatic gene expression in differentiating hESCs. The
optimal concentration of mimic will vary depending on the potency
of the mimic used and the efﬁciency of mimic delivery into the cells.
To determine the optimal concentration that coincides with the468 Molecular Therapy: Nucleic Acids Vol. 12 September 2018beginning symptoms of adverse effects that have a negative impact
on the phenotype, the expression level of miR-7 was examined after
transfection with several concentrations of miR-7 mimic ranging
from 20 to 200 nM (Figure 4D). Analysis of the relationship between
miRNA expression levels and miRNA mimic transfection suggested
that overexpression depends on a threshold miRNA mimic concen-
tration. On one hand, the amount of miRNA mimic introduced
into cultured cells can be controlled simply by adjusting the transfec-
tion concentration; on the other hand, the miRNA mimic concentra-
tion should be sufﬁcient to achieve speciﬁc changes in pancreatic gene
expression. Thus, within our multi-step differentiation protocol
(DD-hESCs), cells were transfected with an miRNA mimic, and
then qRT-PCR was used to determine pancreatic gene changes on
day 22. Results showed that the minimum concentration signiﬁcantly
Figure 4. Integration of miR-7 in the hESC Differentiation Process
(A) Schematic representation of the steps involved in hESC differentiation toward a beta cell fate and the factors involved in this process. (B) Expression time course of high-
stability miR-7 expression after a transient transfection with miRNA miR-7 mimic. Concentration of measured miR-7 by qRT-PCR in hESCs tends to gradually decline over
time, but it occurs with a statistical significance only after day 4. (C) Bar graph of the dose of miRNA transfection ranging from 0 to 200 nM. (D) Effects of upregulated miR-7 on
insulin gene expression in hESC-derived insulin-producing beta-like cells, as determined by qRT-PCR. In each case experiments, n = 6. Values are shown (mean ± SD).
Significant difference in HS181 RNA levels between groups was assessed by one-way ANOVA with Holm-Sı´da´k test, *p < 0.05, **p < 0.01, and ***p < 0.001. (E) Successful
transfection was observed by fluorescence microscopy, and representative images shown are of hESCs 48 hr after transfection with Pierce Dy547-labeled miRIDIAN Mimic
Transfection Controls.
www.moleculartherapy.orgassociated with the upregulation of miR-7 was 20 nM, but we
observed evidence of saturation at 200 nM, the highest concentration
tested (Figure 4C). Interestingly, we noted signiﬁcant upregulation of
late markers of pancreatic endocrine differentiation, such as insulin,
relative to optimal concentration of mimic from 100 nM (Figure 4D).
Therefore, we decided to focus on 100 nM miR-7 mimic, which is
required for the activation of beta cell genes and for DE markers, sug-
gesting that miR-7 may be an important factor in differentiating
hESCs. These results suggest that use of the miR-7 mimic is feasible
and suitable for further study at 100 nM (Figure 4E).
miR-7 Induces Pancreatic Cell Differentiation in hESCs
To detect alterations in expression of pancreatic-related genes after
miR-7 transfection, hESCs were prepared as described above andstimulated to differentiate for 22 days (Figure 4A). To determine
the functional role of miR-7 in the endocrine lineage and verify
whether miR-7 level increases by transfection could induce differen-
tiation into pancreatic endocrine cells, hESCs were transfected for
24 hr with control mimic, miR-7 mimic, miR-7 inhibitor (anti-
miRs (amiR-7), or transfection reagent alone (mock) in the last stage
of the protocol and cultured in suspension with pancreatic differenti-
ation medium for 7 days.
To examine the effect of miR-7 for the last stage of hESC differenti-
ation in vitro, we tested the cell population for expression of islet hor-
mones and key transcription factors. We observed that the expression
of a pancreatic beta cell marker such as insulin was markedly
increased 6.5-fold in hESCs transfected with a high concentrationMolecular Therapy: Nucleic Acids Vol. 12 September 2018 469
Figure 5. Influence of miR-7 on Insulin Secretion in
Response to Glucose Challenge in hESC-Derived
Insulin-Producing Beta-like Cells
(A) hESC-derived insulin-producing beta-like cells were
transiently transfected with miRNA mimic with homolo-
gous sequence to miR-7 or a control. The cells were har-
vested, and the expression profiles of the FOXA2, PDX1,
and insulin during pancreatic differentiation inductionwere
analyzed by qRT-PCRusingRPLP expression as a loading
control. Mock denotes transfection reagent. miR-7 mimic
was transfected using DharmaFECT, and endogenous
miR-7 andmimics were quantified also by qRT-PCR using
RNU48 expression as a loading control (n = 3 per group).
(B) ELISA measurements of insulin secretion at various
glucose concentrations from SD-hESC, DD-hESC +
miR-7, DD-hESC+amiR-7, orDD-hESC+mock.Cultures
were exposed to Krebs solution for 1 hr containing either 2
or 20 mM glucose. After incubation with low or high
glucose, cells were depolarized with 30 mM KCl, as indi-
cated. Cell medium from each group was harvested after
incubation, and insulin concentrationwasmeasured using
a Mercodia ELISA kit (n = 3 per group). (C) Representative
images from confocal immunofluorescence of cells
stained for insulin (red), C-peptide (green), and nuclei
(Hoechst, blue) in SD-hESCs, DD-hESC + miR-7, DD-
hESC + amiR-7, or DD-hESC + mock. (D) Graphs show
the quantification by MetaMorph analysis of average in-
tensity of insulin- and C-peptide-positive cells. Values are
shown (mean ± SD). Statistical difference was assessed
by one-way ANOVA with Holm-Sı´da´k test, *p < 0.05,
**p < 0.01, and ***p < 0.001.
Molecular Therapy: Nucleic Acidsof miR-7 mimic (50–100 nM), when miR-7 is dramatically upregu-
lated 1,490-fold. However, if levels of miR-7 were reduced using
low concentrations of miR-7 mimic (<20 nM), no signiﬁcant change
in insulin expression level was found in the transfected group, even
after 22 days (Figure 4D). To assess the developmental changes in
the insulin-producing beta-like cells resulting from miR-7 modula-
tion, we evaluated the expression of various genes by qRT-PCR.
Importantly, islet cell-speciﬁc marker genes in miR-7 mimic-treated
cells were upregulated, including PDX1 and insulin, which were
respectively increased 7.2- and 6.5-fold compared to their expression
in differentiated hESCs without miR-7 mimic (p < 0.05); moreover,
compared to non-transfected (mock) or control mimic-transfected
hESCs (control mimic), transfection with the miR-7 mimic increased
the expression of pancreatic marker genes. Interestingly, FOXA2, a
major upstream regulator of PDX1, which is highly expressed during
DE differentiation of hESCs, was re-expressed 6.2-fold higher after
miR-7 upregulation in the last stages of the protocol than with the
control or mock treatment (Figure 5A).
To assess the hormone release capacity of hESC-derived insulin-pro-
ducing beta-like cells, we next examined medium samples collected
on day 22 for insulin levels. The potential for improved stimulus-
coupled hormone secretion in hESCs was examined by testing day
22-differentiated cells using a sequential secretion assay including
low and high glucose levels and potassium chloride. Differentiated
cells were examined for their insulin secretion potential (Figure 5B).470 Molecular Therapy: Nucleic Acids Vol. 12 September 2018The increase in insulin production by hESC-derived insulin-produc-
ing beta-like cells transfected with miR-7 (DD-hESC + miR7) that
occurred when glucose was added to the medium at a concentration
of 20 mM was signiﬁcantly greater than that observed at a
lower glucose concentration of 2 mM (1.6 mU/L/105 versus 0.5
mU/L/105, respectively). Furthermore, mock-transfected cells ex-
hibited an increase in insulin secretion, but no signiﬁcant difference
in the insulin concentration was observed between the low and
high glucose conditions (1.9 mU/L/105 and 0.9 mU/L/105, respec-
tively). However, overall, hESC-derived insulin-producing beta-like
cells either with or without miR-7 upregulation responded to depolar-
ization with KCl (2.8 mU/L/105 and 2.3 mU/L/105, respectively). In
contrast, SD-hESCs secreted a very low amount of insulin in response
to low and high glucose challenges (0.4 mU/L/105 in either condi-
tion). In addition, under the same conditions, the inhibition of
miR-7 (DD-hESC + amiR-7) partially inhibited insulin secretion
and blocked glucose-dependent insulin secretion and depolarization
with KCl (1.1 mU/L/105, 1.03 mU/L/105, and 0.5 mU/L/105, respec-
tively) (Figure 5B).
We performed confocal double immunoﬂuorescence of hESC-
derived beta cell-like cells with miR-7 increased (DD-hESC +
miR-7), miR-7 inhibited (DD-hESC + amiR-7), transfection reagent
alone (DD-hESC + mock), and SD-hESCs. Colocalization of insulin
and C-peptide was observed in only hESC-derived insulin-producing
beta-like cells (Figure 5C). However, MetaMorph-based quantitative
Figure 6. Effect of miR-7 Upregulation on Pancreatic
Differentiation in ESCs
(A) Endoderm differentiation in hESCs at day 5: immuno-
fluorescence of SOX17 (green), FISH of miR-7 (red), and
counterstain of nuclei (Hoechst, blue). (B) At 11 days,
DD-hESCs showed colocalization of PDX1 protein and
miR-7, counterstained with Hoechst (blue). (C) At 22 days,
NKX6.1 (green) and miR-7 (red) were expressed in the
hESC-derived insulin-producing beta-like cells and were
counterstained with Hoechst (blue). (D) Graph shows
the quantification by MetaMorph analysis of average
intensity of miR-7 expression. (E) Graph shows the
quantification by MetaMorph analysis of SOX17-, PDX1-,
and NKX6.1-positive cells.
www.moleculartherapy.organalysis conﬁrmed that miR-7 inhibition resulted in signiﬁcantly
fewer insulin- and C-peptide-positive cells than that of the other
treatments (Figure 5D). These results correspond with the observa-
tion that DD-hESCs + amiR-7 secrete lower amounts of insulin
than the other cells and are not glucose responsive, as shown in
Figure 5B.
Finally, we tested whether miR-7 could be detected by FISH at days 5,
11, and 22 during differentiation protocol. On a morphological level,
FISH revealed that miR-7 was expressed at substantially higher levels
in the earlier stages of the protocol at day 5 in DD-hESCs than in
SD-hESCs (Figure 6A), and we observed a gradual decrease in
miR-7 expression from day 5 to day 22 during the differentiation pro-
tocol (Figures 6B and 6C). We evaluated miR-7 expression level after
transfection, and we conﬁrmed miR-7 upregulation in hESC-derived
insulin-producing beta-like cells at day 22 by FISH.
To identify the nature of the cells expressing miR-7, we counter-
stained the FISH sections with antibodies speciﬁc for critical
transcription factors involved in pancreas formation and beta cell dif-
ferentiation in a time course study, and we examined three different
time points during the pancreatic differentiation protocol: 5, 11, and
22 days. Ratio immunoﬂuorescence levels were analyzed using
MetaMorph software (Figures 6D and 6E), and we quantiﬁed theMolecular TherapDEmarker SOX17 as well as the miR-7 co-stain-
ing with nuclear marker Hoechst 33342 in SD-
hESCs and DD-hESCs. There was a signiﬁcant
increase in the number of SOX17- and miR-7-
expressing cells at day 5 (Figures 6D and 6E).
We repeated this experiment at day 11 with
PDX1, which plays an important role in the in-
duction of insulin-producing cells and miR-7
expression; colocalization experiments showed
that miR-7-positive cells (red, FISH with a
locked nucleic acid locked nucleic acid [LNA]
probe) were PDX1 positive, and the PDX1-
negative cells (green, immunohistochemistry)
were miR-7 negative, thus supporting a direct
role for miR-7 in PDX1 expression (Figures 6Band 6E). In the last stages of the differentiation protocol at day 22,
hESC-derived insulin-producing beta-like cells containing popula-
tions of Nkx6.1-positive and miR-7-positive cells could be generated,
and, furthermore, we found that the modulation of miR-7 signiﬁ-
cantly upregulated Nkx6.1, an important transcription factor in
pancreatic development (Figures 6C and 6E). Thus, these results
highlight the ability of speciﬁc miRNAs, such as miR-7, to alter the
expression of genes involved in the pancreatic speciﬁcation in hESCs.
DISCUSSION
Currently, several studies have established different protocols to efﬁ-
ciently generate PP cells from hESCs. In vitro differentiation proto-
cols are intended to mimic conditions in pancreatic development,
and these methods require the addition of expensive growth factors
and generated heterogeneous cell mixtures with low reproducibility.
Our lab has established a new cell culture protocol that induces the
differentiation of hESCs into a beta cell-like phenotype.36 To advance
research, it is essential to be able to control hESC differentiation to
endoderm lineages with high efﬁciency and reproducibility and in
an inexpensive manner. Moreover, understanding the function of
pancreatic islet-speciﬁc miRNAs can help to deﬁne a universal proto-
col for pancreatic differentiation that can be applicable for several cell
lines. In this study, we enumerate certain miRNAs, such as miR-7,
miR-375, miR-148, and others, which might improve furthery: Nucleic Acids Vol. 12 September 2018 471
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needed in diabetes cell therapy. miRNAs play critical roles in normal
stem cell functions during developmental events,37,38 and they are
also important regulators of pancreatic function.25 To further charac-
terize these cells, RNA was extracted and used to perform microarray
analysis to unveil the expression proﬁle of miRNAs during
differentiation.
In this study, proﬁling pancreatic miRNA expression led to the iden-
tiﬁcation of a large fraction of differentially expressedmiRNAs during
hESC differentiation into beta-like cells, as previously reported by
other groups.39,40 In addition, our ﬁndings bring an overview of spe-
ciﬁc miRNAs acting on the maturation and functionality of insulin-
producing cells. Analysis of the signal intensities revealed that the
global miRNA expression patterns with the most considerable differ-
ences were detected in the pancreas and human islets, and the expres-
sion of several miRNAs was more similar between hESC-differenti-
ated cells (DD-hESCs) and human islets. By there being a high
degree of similarity in the overall analysis, these ﬁndings suggest
that DD-hESCsmay be moremature.36 However, there are still differ-
ences between the expression proﬁles of adult pancreatic samples and
DD-hESCs, suggesting that we probably obtained a neonatal cell
population.41,42
In our study, miR-7 and miR-375 were found to be upregulated dur-
ing differentiation into the beta cell-like phenotype. Interestingly,
miR-7 has been reported to be predominantly expressed in the endo-
crine cells of the developing and adult pancreas in humans.21,24 miR-
375 has been reported to be exclusively expressed in pancreatic
islets23,24 and to play an important role in mature islet cell function.43
A former report has indicated that miR-148a is a positive transcrip-
tional regulator of insulin signaling.31 Our results showed elevated
expression of three islet-speciﬁc miRNAs (i.e., miR-7, miR-375, and
miR-148a). Overall, miR-302 was found to be downregulated during
hESC differentiation. Moreover, the downregulation of the miR-302
family in hESCs has been previously reported.44 These miRNAs
constitute a family highly expressed in ESCs, and their expression
levels decline as cells begin to differentiate.45 However, the sustained
expression of some pluripotency-associated miRNA clusters in hESC-
derived insulin-producing beta-like cells indicates that these miRNAs
are not only necessary in the maintenance of pluripotency but also act
as timing regulators of several differentiation processes.46–48 Even the
miR-302 family promotes early events of lineage commitment49–51
and may participate in cell reprogramming and specialization.47
Previous reports suggest that miRNAs play essentials role in the devel-
oping pancreas.31,52,53 Therefore, we examined different pancreatic
tissues and identiﬁed several miRNAs, some of which are highly ex-
pressed in a tissue-speciﬁc manner. This study shows that some of
the most abundant miRNAs in the endocrine pancreas are miR-375,
miR-376, miR-200a/c, miR-214, miR-148, miR-29a/b/c, miR-195,
miR-26a, miR-30d, miR-7, miR-15a/b, miR-16, miR-96, and miR-
663, which is consistent with previous reports.54 An interesting study
of human islets showed that miR-7 is the most abundant endocrine472 Molecular Therapy: Nucleic Acids Vol. 12 September 2018miRNA in islets, while miR-375 is the most abundant intra-islet
miRNA.24 Our miRNA-proﬁling data also showed a higher level of
miR-7 in human islets than in the exocrine pancreas. A recent study
showed the role of miRNAs during pancreatic development by islet-
speciﬁc miRNAs, miR-7, miR-9, miR-375, and miR-376.25 miRNAs
have been shown to be essential in the processes of growth and differ-
entiation in pancreas organogenesis. miR-375 and miR-7 have been
shown to play key roles in pancreatic beta cell development and func-
tion, and both miRNAs exhibit increased expression during pancre-
atic islet development in humans.25 Microarray analysis revealed the
dynamic expression of miRNAs during hESC differentiation, and
several miRNAs are highly and speciﬁcally upregulated during DE
formation. Our study showed that the expression levels of a character-
istic set of miRNAs, miR-7, miR-375, and miR-373, peaked at day 5
and then began to decrease until the end of differentiation, which sug-
gests that these miRNAs play a role that supports the highly efﬁcient
differentiation of hESCs to DE. Interestingly, a member of the miR-
371-miR-373 cluster, which is part of a large family of miRNAs highly
expressed in hESCs (termed ESCC miRNAs),55,56 such as miR-373,
was upregulated in DE, thus also implicating a potential role for this
family in the differentiation of the endoderm lineage.
While these miRNAs seem to be essential for regulating the induction
of events in DE, other miRNAs have been recognized as playing a role
in regulating speciﬁc transcription factors involved in pancreatic differ-
entiation. Among these miRNAs, miR-29a/b are highly expressed and
enriched in islets, and the maintenance of their expression in beta cells
may be implicated in regulating insulin secretion, in islet
development,57 and in the inhibition of miR-148-dependent downre-
gulation of insulin mRNA in primary cultured islets.31 Therefore,
miR-29a/b andmiR-148a could regulate insulin synthesis and its secre-
tion. The miR-200 family is abundantly expressed in the mouse and
human pancreas, and this family regulates the epithelial-to-mesen-
chymal transition and has been implicated in pancreatic carcinogen-
esis.58,59 Our miRNA-proﬁling data showed high levels of miR-29b,
miR-148a, and miR-200a in the later stages of differentiation.
It has been recently reported that the overexpression of miR-375 rep-
resents a new strategy to generate insulin-producing cells in vitro.35,60
We found that miR-7, miR-375, and miR-373 were rapidly increased
to establish the endoderm lineage and then decreased again as differ-
entiation progressed toward a beta cell-like phenotype. Furthermore,
it is important to note that miR-7 is present in the developing endo-
derm lineage and has been suggested as a critical regulator of insulin
and adult beta cell proliferation.61–63 Kredo-Russo et al.64 demon-
strated a potential role of miR-7 in inhibiting endocrine cell differen-
tiation in pancreas explants and transgenic mice, which is mediated
by Pax6 downregulation. The inhibition of miR-7 disrupts pancreatic
differentiation during early developmental stages of mouse, and it
seems to have a beta cell-speciﬁc effect causing an overall downregu-
lation of insulin production;34 besides, miR-7 inhibition could pro-
mote adult beta cell proliferation via mTOR signaling.63 All together,
the data suggest a speciﬁc effect of miR-7 on endocrine cell differen-
tiation and function, and they demonstrate the dual regulatory
www.moleculartherapy.orgfunction of miR-7. Mature miR-7 is highly conserved among mam-
mals, such as human, rat, and mouse, among which miR-7 shares
the same seed sequence. This might result in a similar function in
these species.
Gene expression analysis revealed that miR-7 is upregulated during
pancreatic differentiation of hESCs, and, in the ﬁnal stages of differ-
entiation, miR-7 was overexpressed in hESCs. This system provides
the opportunity to examine the miRNAs expressed in a cell popu-
lation that are capable of inducing lineage-speciﬁc cell differentia-
tion. It was observed that, with the increase in miR-7 expression,
there was a signiﬁcant increase in the expression of pancreatic
markers, including FOXA2, PDX1, and insulin. Notably, miR-7
may have a positive effect on the stimulated release of insulin.
Taken together, these data suggest that overexpression of miR-7
has dose-dependent effects on the expression of insulin and that
high concentrations of miR-7 result in an increased insulin release
during a glucose challenge, which suggests that miR-7 improves
the maturation of hESC-derived insulin-producing beta-like cells
to functionally respond to elevated glucose levels. In contrast, the
inhibition of miR-7 is unfavorable for insulin secretion. We note
that the levels of insulin secreted in response to glucose challenges
in miR-7-inhibited cells in vitro was generally lower than that of
cells expressing either basal or overexpressed levels of miR-7. Our
ﬁndings indicate that the upregulation of miR-7 improves beta
cell function, while the inhibition of miR-7 is deleterious for beta
cell function and blocks glucose-induced insulin secretion. There-
fore, while miR-7 is beneﬁcial and critical for the generation and
speciﬁcation of DE and PP cells, late-stage increases in the expres-
sion of miR-7 are critical to regulate functional aspects of the beta
cell phenotype.
In conclusion, our results suggest a pivotal role of miR-7, miR-375,
and miR-373 in the establishment of the endoderm lineage as well
as its terminal differentiation, and they provide compelling evidence
to support our ﬁnding that miR-7 positively regulates markers for
pancreatic differentiation and improves beta cell function. We are
aware that much work remains to be done, but these ﬁndings may in-
crease our understanding of the molecular mechanisms that control
pancreatic development.
MATERIALS AND METHODS
Cell Culture
The hESC line HS181 was derived in the Fertility Unit of Karolinska
University Hospital, Huddinge at the Karolinska Institute, after
approval of a project entitled “Derivation and early differentiation
and characterization of hESC lines” by the Karolinska Institute
Research Ethics Board South, Drno 454/02. HS181 was derived
from an embryo that could not be used for infertility treatment of a
couple. Both partners of the couple signed a consent form to donate
the embryo for the derivation of a possibly permanent stem cell line to
be used in stem cell research. HS181 is included in the European
Union hESC registry (https://hpscreg.eu/).65 The hiPSC line
MSUH-001 was obtained from the ISCIII National Biobank (SpanishMinistry of Health). HS181 and MSUH-001 were cultured, according
to previous reports.65,66
ESC Culture and Differentiation
The UN-hESCHS181 line wasmaintained and passaged as previously
described.65,66 The protocol of hESC directed differentiation into in-
sulin-producing beta-like cells (DD-hESCs) and the protocol of spon-
taneous differentiation (SD-hESCs) were achieved, as described by
Pezzolla et al.36 Cells generated at the ﬁnal stage were then transfected
with miR-7 mimic (10–100 nM) and cultured in differentiation me-
dium to facilitate the formation of cell clusters and to mature the
beta cell-like phenotype.
RNA Extraction and qRT-PCR
Total RNA from cells was isolated using TRIzol (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions. Synthesis of
cDNA from mRNA was obtained by using Moloney Murine Leuke-
mia Virus Reverse Transcriptase (Promega, Madison, WI, USA)
and random hexamers according to the manufacturer’s instructions.
Analysis (qRT-PCR) was performed in triplicate using a ViiA 7 Real-
Time PCR System (Applied Biosystems, Foster City, CA, USA), ViiA
7 Software (Applied Biosystems), and SYBR Green SuperMix Low
ROX (BIOLINE, Luckenwalde, Germany), using the standard instru-
ment protocol. mRNA levels were normalized to the expression of
RPLP (TATAA-Biocenter, Gothenburg, Sweden).
All reactions were performed in a 20-mL reaction mixture volume
with 400 nM forward primer and 400 nM reverse primer for
mRNA. Primer sequences are described in Table S2. miRNA reverse
transcription reactions were performed using a Universal cDNA Syn-
thesis kit (Exiqon Vedbaek, Denmark), in accordance with the man-
ufacturer’s protocols. Prior to qRT-PCR reactions, cDNA was diluted
1 in 80 for Exiqon assays. miRCURY LNA Universal RT microRNA
PCR assays were performed using SYBR Green MasterMix Universal
RT (Exiqon), according to the manufacturer’s instructions. Reactions
were performed, according to themanufacturer’s instructions, using a
ViiA 7 Real-Time PCR System (Applied Biosystems). Table S3 gives
details of the qRT-PCR primers used. The average expression levels of
miRNAs in cells were normalized to U48 small nuclear RNA
(snRNA). ViiA 7 Software version 1.2 (Life Technologies, Carlsbad,
CA, USA) was used to calculate the quantiﬁcation cycle (Ct) value,
which is deﬁned as the number of cycles at which the ﬂuorescence
signal is signiﬁcantly above the threshold; expression of each
mRNA and miRNA was deﬁned from the threshold cycle (Ct), and
relative expression levels were calculated using the 2DDCt method
after normalization with reference to expression of internal control.
Data are expressed as the means ± SD of three replicates of each
experiment.
Microarray Analysis
Microarray image analysis was conducted using an Agilent’s 60-mer
SurePrint (Agilent Technologies, Santa Clara, CA, USA) scanner to
acquire the microarray images, which were subsequently processed
with GenePix Pro software 7.0 (Molecular Devices) to generate theMolecular Therapy: Nucleic Acids Vol. 12 September 2018 473
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were conducted according to the manufacturer’s instructions.
Background intensity values were corrected using an algorithm nor-
mexp67,68 and were used for the analysis, and normalization was con-
ducted using quantile normalization.69 Similarly, expressed genes
were ﬁltered based on the SD among three biological replicates
with >0.58-fold and p < 0.05 changes in upregulated miRNAs, and
fold changes of <0.58-fold and p < 0.05 of downregulated miRNAs
were used for further analysis.
Detection of Insulin Secretion
Supernatants were collected at day 22 following differentiation induc-
tion in SD-hESCs and DD-hESCs with or without miR-7 transfection,
and they were stored at20C until assay of insulin secretion. Insulin
secretion was measured as previously described.36 Brieﬂy, clusters of
cells were plated onto Matrigel-coated dishes and rinsed twice in
Krebs solution (NaCl 129 mM, NaHCO3 5 mM, KCl 4.8 mM,
KH2PO4 1.2 mM, MgSO4 1.2 mM, CaCl2 1 mM, HEPES 10 mM,
and BSA 0.1% [pH 7.4]). Cells were incubated for 60 min at 37C
with Krebs solution containing 2 or 20 mM glucose. This sequence
was repeated one additional time (data not shown). Finally, cells
were exposed to 2 mM glucose challenge and depolarized with
30 mM KCl. Insulin levels were measured in technical duplicate
and biological triplicates using a commercially available human insu-
lin ELISA kit (Mercodia AB, Uppsala, Sweden).
Immunofluorescence and FISH
Non-radioactive FISH was performed using a QuantiGene ViewRNA
FFPE Assay (Affymetrix Panomics, Santa Clara, CA, USA) according
to the manufacturer’s instructions. A probe set was designed by Affy-
metrix that corresponded to human mature miR-7, miR-148a, and
miR-375; the sequences were 50-uggaagacuagugauuuuguugu-30,
50-ucagugcacuacagaacuuugu-30, and 50-uuuguucguucggcucgcguga-30,
respectively. As a negative control, a probe set was designed against a
target that was absent in our cell line (50-cagaacgaacaccacauuuugac-
30, DapB) and was applied instead of the miR-speciﬁc probes. Cells
that are cultured in suspension were enzymatically dissociated with
Accutase (STEMCELL Technologies, San Diego, CA, USA) and
seeded into m-Dish 35 mm (Ibidi, Martinsried, Germany) coated
with BD Matrigel (BD Biosicences, San Diego, CA, USA) for 12 hr
to promote adhesion. Adherent cells (at a different point of differen-
tiation) were ﬁxed for 20 min in fresh 4% paraformaldehyde. After
hybridization, washing, preampliﬁer hybridization, ampliﬁer hybrid-
ization, and alkaline phosphatase reactions, cells were washed thrice
for 5 min in PBS.
Next, cells were blocked for 1 hr in PBS supplemented with 4% BSA,
permeabilized with 0.5% Triton X-100 in PBS, and incubated with
primary antibodies overnight at 4C. After rewashing with PBS, cells
were then incubated with ﬂuorochrome-conjugated secondary anti-
bodies (Invitrogen) for 1 hr at room temperature. Following PBS
wash, cell nuclei were stained with Hoechst 33342 (1 mg/mL). Primary
and secondary antibodies used in this study are listed in Table S4.
Fluorescence images were captured with a Leica SP5 confocal micro-474 Molecular Therapy: Nucleic Acids Vol. 12 September 2018scope and Leica Application Suite software (Leica, Mannheim, Ger-
many) or an inverted ﬂuorescence microscope Olympus IX71 and
DPManager software (Olympus, Tokyo, Japan). After acquisition,
images were analyzed using Meta Imaging Software MetaMorph
(MDS Analytical Technologies, Sunnyvale, CA, USA). Fluorescence
quantiﬁcation was conducted using MetaMorph software by
measuring integrated ﬂuorescence intensities in a deﬁned region of
2 by 2 pixels and subtracting minimum background ﬂuorescence
from every value. Quantiﬁcation was performed for at least 50 cells
per experiment from three independent experiments (biological
replicates).
Transfection of miRNA
2-’O-Methyl oligonucleotides complementary to miR-7 or miRNA
negative control was chemically synthesized by Dharmacon (Dhar-
macon, Lafayette, CO, USA). The sequence of mature miR-7 is 50-ug-
gaagacuagugauuuuguugu-30. For gain-of-function experiments using
miR mimics or for inhibition experiments using anti-miRs (amiRs),
hESC colonies were detached from culture dishes and grown in sus-
pension culture in ultra-low attachment multi-well plates; cells were
transfected with 100 nM miR-7, amiR-7, miRNA negative control,
or transfection reagent alone (mock) using DharmaFECT (Dharma-
con) in RPMI-1640 containing 12% knockout serum replacement
(KSR) for 24 hr. To investigate any response of miR-7 upregulation,
the medium was changed after 24 hr, and hESCs were cultured for an
additional 7 days before being harvested.
Target Prediction of miRNA and Functional Annotation of the
Predicted Target
To facilitate the interpretation of biological functions affected by
miRNAs showing signiﬁcantly differential expression by microarray
and conﬁrmed by qRT-PCR, target prediction and functional anno-
tation were performed using the miRSystem database (version
20160513),70 which is an integrated system used to characterize the
enriched functions and pathways of miRNA targets. In target predic-
tion, the miRSystem database integrates 2 experimentally validated
databases, TarBase (version 7.0) and miRecords (April 27, 2013
release), and 7 target gene prediction algorithms, including
DIANA-microT (version 5.0), miRanda (August 2010 release),
miRBridge (April 2010 release), PicTar (March 2007 release), PITA
(August 2008 release), RNA22 (version 2.0), and Targetscan (version
7.1). In functional annotation, the miRSystem database integrates 5
databases, including KEGG, BIOCARTA, Pathway Interaction Data-
base (human only), Reactome (human only), and GO.
To identify signiﬁcantly enriched pathways or biological function,
several statistical approaches, including O:E (observed to expected)
ratios of gene targets, hypergeometric and empirical value from
permutation, and pathway ranking score from miRNA relative
expression value (fold change), were also provided in the miRSystem
database. In the present study, miRNAs and their fold changes were
submitted to the miRSystem database. Only validated targets or
miRNA-target interactions identiﬁed by at least 4 prediction pro-
grams were considered for annotation of the KEGG pathway and
www.moleculartherapy.orgGO molecular function. Moreover, parameter settings were 25–500
genes in biological functions/pathways, O:E ratios R 1.8. Finally,
target predictions of differentially expressed miRNAs were uploaded
to the online DAVID tool (DAVID version 6.8, https://david.ncifcrf.
gov/) to perform GO terms of the miRNA candidates putative
target genes and REViGO to generate semantic similarity-based
scatterplots.
Statistical Analysis
All experiments were performed at least three times. Data are ex-
pressed as the mean ± SD. Statistical analysis was performed by
GraphPad Prism 6 (San Diego, CA, USA) using one-way ANOVA
followed by Holm-Sídák test, as appropriate, to determine statistical
signiﬁcance for multiple comparisons. Student’s t tests were per-
formed for comparisons between two groups. p values < 0.05 were
considered to be statistically signiﬁcant.
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